About the Company
Check-Cap is a clinical stage medical diagnostics company leading the development of the first ingestible imaging capsule that utilizes low-dose X-rays for CRC screening.
The Check-Cap device requires no bowel preparation or invasive procedures, and is designed to detect clinically significant polyps with a high degree of sensitivity. Check-Cap’s advanced technology has been proven in animals, and is designed to offer several advantages compared to current screening procedures.
Founded in early 2005, Check-Cap recruited a team of world-class experts in physics, software engineering, electronics, mechanics and physiology, who have been developing a multi-disciplinary imaging solution for imaging and screening of the colon. The system includes a capsule, a receiver, proprietary imaging software and an associated database for web based access and analysis.
Check-Cap’s advanced technology has been proven in animals and promises to offer several significant advantages compared to other colonic screening procedures.
Colorectal cancer is the Western world’s second largest cancer killer, despite being largely preventable and/or treatable with early screening. Check-Cap’s technology is designed to be the first to offer CRC screening through a structural exam without the pain, discomfort and embarrassment experienced during currently available screening methods, and thus is uniquely positioned to increase screening compliance without compromising accuracy. We intend to develop our technology into the next breakthrough, gold standard in colon cancer screening to address the need of an estimated 35 million patients annually in a fast-growing $25B market.
ISFIYA, ISRAEL / ACCESSWIRE / February 8, 2017 / Check-Cap Ltd. (the “Company” or “Check-Cap”) (NASDAQ: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening, announced today...
Life Sciences & Healthcare Investor Conference & Webinar: Nasdaq and OTCQX Companies Present February 2nd
NEW YORK, Jan. 30, 2017 /PRNewswire/ — PR Newswire and BetterInvesting (NAIC) today announced the agenda for the upcoming VirtualInvestorConferences.com, the evergreen online investor conference series. Individual investors, institutional investors, advisors, and analysts are invited. The show opens on...
Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual VirtualInvestorConferences.com ISFIYA, Israel and BOSTON, Jan. 30, 2017 /PRNewswire/ — Check-Cap Ltd. (CHEK), engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening...
Check-Cap Enrolls First Patient in Clinical Trial to Support CE Mark of Its C-Scan® Colorectal Cancer Screening System
ISFIYA, Israel, January 17, 2017 /PRNewswire/ — Check-Cap Ltd. (the “Company” or “Check-Cap”) (NASDAQ: CHEK, CHEKW), a clinical stage medical diagnostics company developing a capsule-based system for preparation-free, colorectal cancer (CRC) screening, today announced the enrollment of the first...